The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death

Glioblastoma (GBM) is the most common, but extremely malignant, brain tumor; thus, the development of novel therapeutic strategies for GBMs is imperative. Many tyrosine kinase inhibitors (TKIs) have been approved for various cancers, yet none has demonstrated clinical benefit against GBM. Anaplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawauchi, Daisuke, Takahashi, Masamichi, Satomi, Kaishi, Yamamuro, Shun, Kobayashi, Tatsuya, Uchida, Eita, Honda‐Kitahara, Mai, Narita, Yoshitaka, Iwadate, Yasuo, Ichimura, Koichi, Tomiyama, Arata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177803/
https://www.ncbi.nlm.nih.gov/pubmed/33728771
http://dx.doi.org/10.1111/cas.14885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177803/
https://www.ncbi.nlm.nih.gov/pubmed/33728771
http://dx.doi.org/10.1111/cas.14885

Ejemplares similares